Novo CEO pressed by Senate to chop costs of being overweight, diabetes prescription drugs CEO Lars Fruergaard Jørgensen advised lawmakers the company would look at new talks with insurers concerning the record costs of Wegovy and copyright whenever they pledge to keep the medicines on their formularies. Listen to the https://dantelnnoo.thechapblog.com/30062856/the-healthcare-news-diaries